FibroGen, Inc (NASDAQ:FGEN) Director Thomas F. Kearns, Jr. sold 18,000 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $45.22, for a total value of $813,960.00. Following the transaction, the director now owns 156,564 shares of the company’s stock, valued at approximately $7,079,824.08. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of FibroGen, Inc (FGEN) opened at $46.87 on Monday. FibroGen, Inc has a 1 year low of $19.25 and a 1 year high of $60.15. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16.
Several research analysts have recently weighed in on the company. Leerink Swann reiterated an “outperform” rating and set a $82.00 price target (up previously from $52.00) on shares of FibroGen in a research note on Tuesday, August 8th. William Blair restated an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Citigroup Inc. raised their target price on FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research note on Tuesday, August 8th. Jefferies Group LLC restated a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research note on Tuesday, August 8th. Finally, Stifel Nicolaus raised their target price on FibroGen from $38.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $65.67.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.